IPP Bureau
Indian Pharmacopoeia 2026 debuts with 121 new monographs targeting TB, diabetes, and cancer
By IPP Bureau - January 04, 2026
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
BioVarta 2025 puts the spotlight on translating biotech innovation into impact
By IPP Bureau - January 04, 2026
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Zydus Group elevates Dr. Tushar Nahata to Vice President
By IPP Bureau - January 04, 2026
His professional background also includes key experience at Matrix Labs and Sun Pharma
Strides appoints Yajuvendra Singh M R as VP - Digital Transformation
By IPP Bureau - January 04, 2026
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
Caplin Point Labs acquires 10 ANDAs, targets $473M US market
By IPP Bureau - January 03, 2026
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
Biotium launches GlycoLiner kits for fast & selective cell surface glycoprotein labelling
By IPP Bureau - January 03, 2026
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%
By IPP Bureau - January 03, 2026
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
Cupid reports record Q3, eyes GCC expansion with Saudi FMCG facility
By IPP Bureau - January 03, 2026
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Govt. issues draft amendment to remove cough syrups from Schedule K
By IPP Bureau - January 01, 2026
Once finalized, cough syrups will no longer be available for over-the-counter sale
China’s top court backs Novo Nordisk, upholds semaglutide patent in landmark IP ruling
By IPP Bureau - January 01, 2026
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
Rare arm cancer defeated: Indore doctors save patient’s arm with complex surgery
By IPP Bureau - January 01, 2026
The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement
Savara resubmits FDA application for potential treatment in rare lung disease patients
By IPP Bureau - January 01, 2026
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Ultragenyx’s Setrusumab falls short in Phase 3 osteogenesis imperfecta trials
By IPP Bureau - January 01, 2026
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs
By IPP Bureau - January 01, 2026
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Establishment Labs seeks FDA nod for Motiva breast reconstruction implants
By IPP Bureau - January 01, 2026
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
